Beijing Hotgen Biotech Co., Ltd.
SSE:688068.SS
136.4 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 510.9 | 541.251 | 3,556.552 | 5,369.204 | 513.534 | 210.412 | 187.123 | 142.089 | 122.196 |
| Cost of Revenue
| 228.068 | 209.844 | 1,646.279 | 2,172.495 | 189.947 | 56.55 | 49.131 | 36.834 | 29.284 |
| Gross Profit
| 282.832 | 331.407 | 1,910.273 | 3,196.708 | 323.587 | 153.863 | 137.992 | 105.255 | 92.912 |
| Gross Profit Ratio
| 0.554 | 0.612 | 0.537 | 0.595 | 0.63 | 0.731 | 0.737 | 0.741 | 0.76 |
| Reseach & Development Expenses
| 0 | 131.447 | 191.139 | 131.916 | 47.612 | 28.991 | 18.383 | 15.633 | 13.295 |
| General & Administrative Expenses
| 0 | 41.228 | 151.511 | 43.61 | 20.081 | 13.437 | 7.611 | 16.989 | 14.875 |
| Selling & Marketing Expenses
| 0 | 171.154 | 268.918 | 233.795 | 113.088 | 70.138 | 53.986 | 39.613 | 32.029 |
| SG&A
| 205.133 | 212.382 | 420.429 | 277.405 | 133.168 | 83.576 | 61.597 | 56.602 | 46.903 |
| Other Expenses
| 263.289 | -29.632 | 59.535 | 115.505 | 23.135 | 3.984 | -0.31 | -0.011 | 3.855 |
| Operating Expenses
| 468.422 | 314.197 | 671.103 | 524.827 | 203.916 | 116.551 | 82.744 | 71.221 | 60.872 |
| Operating Income
| -171.944 | 17.21 | 1,090.853 | 2,584.419 | 127.951 | 37.372 | 55.808 | 34.599 | 30.08 |
| Operating Income Ratio
| -0.337 | 0.032 | 0.307 | 0.481 | 0.249 | 0.178 | 0.298 | 0.244 | 0.246 |
| Total Other Income Expenses Net
| -4.068 | -3.705 | -15.633 | -2.607 | -0.527 | 0.488 | -0.31 | -0.011 | 3.855 |
| Income Before Tax
| -176.012 | 13.505 | 1,075.221 | 2,581.812 | 127.425 | 37.86 | 55.498 | 34.588 | 33.935 |
| Income Before Tax Ratio
| -0.345 | 0.025 | 0.302 | 0.481 | 0.248 | 0.18 | 0.297 | 0.243 | 0.278 |
| Income Tax Expense
| 19.927 | -1.549 | 150.104 | 379.435 | 16.129 | 4.112 | 7.31 | 4.515 | 5.135 |
| Net Income
| -179.231 | 27.383 | 944.737 | 2,185.763 | 112.067 | 33.878 | 48.141 | 30.072 | 28.799 |
| Net Income Ratio
| -0.351 | 0.051 | 0.266 | 0.407 | 0.218 | 0.161 | 0.257 | 0.212 | 0.236 |
| EPS
| -1.94 | 0.31 | 10.55 | 23.75 | 1.22 | 0.37 | 0.7 | 0.43 | 0.44 |
| EPS Diluted
| -1.94 | 0.31 | 10.28 | 23.75 | 1.22 | 0.37 | 0.7 | 0.43 | 0.44 |
| EBITDA
| -96.663 | 85.04 | 1,197.829 | 2,657.468 | 157.017 | 64.39 | 78.544 | 50.635 | 41.763 |
| EBITDA Ratio
| -0.189 | 0.157 | 0.337 | 0.495 | 0.306 | 0.306 | 0.42 | 0.356 | 0.342 |